Contact
Please use this form to send email to PR contact of this press release:
GeneTx and Ultragenyx Announce Investigational New Drug (IND) Application Active for GTX-102 in Patients with Angelman Syndrome
TO:
Please use this form to send email to PR contact of this press release:
GeneTx and Ultragenyx Announce Investigational New Drug (IND) Application Active for GTX-102 in Patients with Angelman Syndrome
TO: